📊 MNPR Key Takeaways
Is Monopar Therapeutics (MNPR) a Good Investment?
Monopar Therapeutics is a pre-revenue pharmaceutical company with significant ongoing losses and negative cash flow, indicating it is in early clinical development stages. While the company maintains a strong cash position of $61.8M and minimal debt, the current burn rate of $12.2M annually combined with zero revenue creates substantial viability risks without successful commercialization or additional financing.
Monopar is a pre-revenue biotech with substantial liquidity ($61.8M cash), zero debt, and minimal liabilities, supporting a multi-year operating runway. Losses remain material but improved YoY, indicating some cost discipline; however, without revenue, the path to profitability depends on clinical progress not reflected in these financials. On fundamentals alone, strong balance sheet strength offsets ongoing burn, meriting a neutral stance.
Why Buy Monopar Therapeutics Stock? MNPR Key Strengths
- Strong balance sheet with $61.8M in cash and negligible debt (Debt/Equity: 0.00x)
- Excellent liquidity position with 51.35x current ratio, providing runway for development activities
- Minimal liabilities ($2.9M) relative to assets ($140.7M) demonstrates conservative financial management
- Recent insider activity (5 Form 4 filings in 90 days) suggests ongoing management engagement
- Exceptional liquidity (current/quick ~51x) and $61.8M cash
- Debt-free with minimal liabilities vs $140.7M assets
- Net loss improved ~12% YoY, suggesting expense control
MNPR Stock Risks: Monopar Therapeutics Investment Risks
- Zero revenue generation indicates company is pre-commercialization with no approved products generating sales
- Persistent operating losses (-$16.7M) and negative free cash flow (-$12.2M) require continued capital consumption
- Cash runway concerns: at current burn rate of $12.2M annually, existing cash reserves provide only ~5 years of operations without additional revenue or financing
- Pharmaceutical development risk: company faces typical biotech risks of clinical trial failures, regulatory rejection, and time-to-market delays
- Negative ROE (-10.0%) and ROA (-9.7%) demonstrate shareholder value destruction in current operations
- No revenue with sustained operating losses and negative ROE/ROA
- Cash burn (-$12.2M OCF) could accelerate, raising dilution risk
- Outcome and timing risk tied to clinical/regulatory milestones
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway remaining
- Clinical trial progress and regulatory milestones for pipeline candidates
- Quarterly revenue achievement and commercialization timeline updates
- Changes in cash position and potential dilutive financing activities
- Operating loss trends and pathway to profitability demonstration
- Operating cash burn (TTM and quarterly trend)
- Cash and equivalents vs projected runway (12–24 months)
Monopar Therapeutics (MNPR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 51.35x current ratio provides a solid financial cushion.
MNPR Profit Margin, ROE & Profitability Analysis
MNPR vs Healthcare Sector: How Monopar Therapeutics Compares
How Monopar Therapeutics compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Monopar Therapeutics Stock Overvalued? MNPR Valuation Analysis 2026
Based on fundamental analysis, Monopar Therapeutics has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Monopar Therapeutics Balance Sheet: MNPR Debt, Cash & Liquidity
MNPR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Monopar Therapeutics's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.11 indicates the company is currently unprofitable.
MNPR Revenue Growth, EPS Growth & YoY Performance
MNPR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.3M | $-0.37 |
| Q2 2025 | N/A | -$1.6M | $-0.35 |
| Q1 2025 | N/A | -$1.6M | $-0.38 |
| Q3 2019 | N/A | -$640.2K | N/A |
| Q2 2019 | N/A | -$640.2K | N/A |
| Q1 2019 | N/A | -$640.2K | N/A |
| Q3 2018 | N/A | -$640.2K | N/A |
| Q2 2018 | N/A | -$591.4K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Monopar Therapeutics Dividends, Buybacks & Capital Allocation
MNPR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Monopar Therapeutics (CIK: 0001645469)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MNPR
What is the AI rating for MNPR?
Monopar Therapeutics (MNPR) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MNPR's key strengths?
Claude: Strong balance sheet with $61.8M in cash and negligible debt (Debt/Equity: 0.00x). Excellent liquidity position with 51.35x current ratio, providing runway for development activities. ChatGPT: Exceptional liquidity (current/quick ~51x) and $61.8M cash. Debt-free with minimal liabilities vs $140.7M assets.
What are the risks of investing in MNPR?
Claude: Zero revenue generation indicates company is pre-commercialization with no approved products generating sales. Persistent operating losses (-$16.7M) and negative free cash flow (-$12.2M) require continued capital consumption. ChatGPT: No revenue with sustained operating losses and negative ROE/ROA. Cash burn (-$12.2M OCF) could accelerate, raising dilution risk.
What is MNPR's revenue and growth?
Monopar Therapeutics reported revenue of $0.0.
Does MNPR pay dividends?
Monopar Therapeutics does not currently pay dividends.
Where can I find MNPR SEC filings?
Official SEC filings for Monopar Therapeutics (CIK: 0001645469) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MNPR's EPS?
Monopar Therapeutics has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MNPR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Monopar Therapeutics has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MNPR stock overvalued or undervalued?
Valuation metrics for MNPR: ROE of -10.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MNPR stock in 2026?
Our dual AI analysis gives Monopar Therapeutics a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MNPR's free cash flow?
Monopar Therapeutics's operating cash flow is $-12.2M, with capital expenditures of N/A.
How does MNPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -10.0% (avg: 15%), current ratio 51.35 (avg: 2).